FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer By Ogkologos - April 8, 2026 291 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum April 13, 2022 Evaluation of Pemigatinib Efficacy in FGFR-Altered Advanced Solid Tumours Led to... May 17, 2024 Her Mother Died of Breast Cancer When She Was Five. 16... June 25, 2019 Hospice Service Provides “Bucket List” Tattoo for 77-Year-Old Woman with Breast... June 11, 2019 Load more HOT NEWS EMA Recommends Extension of Indications for Ribociclib to Include Use in... Long-Term Clinical Benefit with Nivolumab Plus Ipilimumab Extends Beyond Treatment Discontinuation... No Glucose? Pancreatic Cancer May Have a Ready Energy Alternative How Adolescent and Young Adult Cancer Survivors Can Cope With the...
